Absolute Bioavailability of Reslizumab in Healthy Subjects

NCT01990443 ↗

Phase 1 Completed 75 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedParallel-groupOpen-label

Summary

The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants

Timeline

Start: 2013-06
Primary completion: 2013-12
Completion: 2014-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reslizumab	Monoclonal antibody	220 mg	Intravenous

Indications

No indication recorded.